February 26, 2024

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

ACTIVATION

GYNECOLOGIC

NRG-GY028: Re-Activation with Protocol Amendment 2. Based on the study’s Phase I results, Dose Level 1 (ipatasertib 400 mg + megestrol acetate 160 mg) is moving forward into the Phase II portion which is open to all NCTN participants. See Study Memorandum dated February 26, 2024 (posted on CTSU).

AMENDMENTS

1. GENITOURINARY

NRG-GU012 - Sites in Canada - The NOL and additional forms for amendment 4 are posted on CTSU. Please complete the CTSI and Protocol signature page and submit via the Regulatory submission portal.

RTOG 1216 - Sites in Canada only: The NOL and additional forms for amendment 10 are posted on CTSU. Please complete the CTSI, Protocol signature page and IB signature page and submit via the Regulatory submission portal.

2. GYNECOLOGIC

NRG-GY026: Amendment 5; version date: January 18, 2024 (posted on CTSU)

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only Read More

2. BIOSPECIMEN BANK

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

Updated Pathology Instructions

Pathology and Correlative Science Instructions were updated to include the new Biobank Pittsburgh address for the NRG studies listed below. Please be advised that the new versions (dated February 19, 2024) have been posted to the following study pages on the CTSU website:

• NRG-BR007
• NRG-BR008
• NRG-BR009
• NRG-GI002
• NRG-GI004
• NRG-GI005
• NRG-GI008 (dated February 22, 2024)
• NSABP B-51
• NSABP B-52
• NSABP B-55

3. CANCER CONTROL & PREVENTION

NRG-CC010: The study is now open to NRG sites in Japan and South Korea. The optional biospecimen collection does not apply to sites participating in these countries.

4. GASTROINTESTINAL

NRG-GI008 (CIRCULATE-NORTH AMERICA): Updated Pathology and Correlative Science Instructions (dated February 22, 2024) posted on CTSU.

5. GYNECOLOGIC

EAY191-N4: Appendix XI, Section II, 1^st bullet: Reports should be REDACTED. Section 10.2: Footnote 2 will be deleted. These changes will be made with the next amendment.

GOG-0210: Reminder: Biospecimens, biomarker data, clinical data, and epidemiologic data are available for request. Please visit the NRG Oncology website for more information on this important study with the overall goal of improving the outcome and/or quality of life for patients with endometrial cancer.

NRG-GY031: Please note, there is an error in the section 4.2 table and the Biospecimen Collection and Submission Manual. The Part I PK collection is to be done on Cycle 1, Day 1, and Cycle 1, Day 8. This will be updated with the next amendment.

6. HEAD & NECK

NRG-HN008

Reminder: please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important.

7. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on NRG-HN001, NRG-HN002, NRG-CC003, NRG-CC005, NRG-BR009, NRG-CC011, and NRG/SWOG S1914. Space is limited so register now and reserve your seat. The next webinar training is scheduled for Wednesday, March 13, 2024.

Developing and Running an R01 Through NRG NCORP – Register for the webinar to be held on Thursday, April 11, 1-2:30pm ET

Participants will learn about the NRG NCORP concept review process with a specific focus on R01s.

Dr. Von Ah and Dr. Sikorskii will present their recent experiences R01 concepts through the NRG NCORP, along with lessons learned and benefits of utilizing the NRG NCORP process. A panel of professionals will also be available to discuss their experiences and answer questions from attendees.

Register in advance for this webinar. After registering, you will receive an email with the meeting link.

NRG Oncology Confidential Member Survey

Please read our survey FAQ’s. All NRG Members should have received an email from the University of Chicago’s Survey Lab <noreply@qemailserver.com> containing a unique survey link. If you have not already completed the survey, please check your inbox and possibly your spam/junk mailbox for the email so that you can help us collect this important information. Please send any additional questions to nrg-broadcasts@nrgoncology.org.

REMINDER: Any manuscript or abstract resulting from research done under the auspices of our NCI grant awards must be processed through the NRG Publications Office before being submitted to the journal or association. Please remember to cite any pertinent grant numbers in these publications.

Please note the following upcoming meetings and abstract submission deadlines

UPCOMING MEETINGS

American Association for Cancer Research (AACR); Apr 5-10, 2024; San Diego, CA

American Association for Thoracic Surgery (AATS); Apr 27-30, 2024; Toronto, ON

American Brachytherapy Society (ABS) World Congress; Jul 10-13, 2024; National Harbor, MD

American College of Radiology (ACR); Apr 13-17, 2024; Washington, DC

American Head and Neck Society (AHNS); May 15-16, 2024; Chicago, IL

American Radium Society (ARS); May 2-5, 2024; Palm Springs, CA

American Society of Breast Surgeons (ABS); Apr 10-14, 2024; Orlando, FL

American Society of Clinical Oncology (ASCO); May 31-Jun 4, 2024; Chicago, IL

American Society of Colon and Rectal Surgeons (ASCRS); Jun 1-4, 2024; Baltimore, MD

European Society of Gynaecological Oncology (ESGO); Mar 7-10, 2024; Barcelona, Spain

European Society for Radiotherapy and Oncology (ESTRO); May 3-7, 2024; Glasgow, Scotland

Society for Clinical Trials (SCT); May 19-22, 2024; Boston, MA

Society of Gynecologic Oncology (SGO); Mar 16-18, 2024; San Diego, CA

Society of Surgical Oncology (SSO); Mar 20-23, 2024; Atlanta, GA

UPCOMING ABSTRACT SUBMISSION DEADLINES

American Society for Radiation Oncology (ASTRO); Sep 29-Oct 2, 2024; Washington, DC; due to publications committee Feb 27, 2024; submission deadline Mar 12, 2024; LBA Jul 12, 2024

EORTC-NCI-AACR Symposium on Molecular Targets and therapies; Oct 23-25, 2024; Barcelona, Spain; due to publications committee Jun 13, 2024; submission deadline Jun 27, 2024; LBA Sep 26, 2024

European Society for Medical Oncology (ESMO); Sep 13-17, 2024; Barcelona, Spain; due to publications committee Apr 23, 2024; submission deadline May 7, 2024, 21:00 CET; LBA Aug 7, 2024, 21:00 CET (placeholder required)

European Society for Medical Oncology (ESMO) Breast Cancer; May 15-17, 2024; Berlin, Germany; LBA Apr 17, 2024, 21:00 CET (placeholder required)

European Society for Medical Oncology (ESMO) Gastrointestinal; Jun 26-29, 2024; Munich, Germany; submission deadline Apr 9, 2024, 21:00 CET; LBA Jun 6, 2024, 21:00 CET (placeholder required)

European Society for Medical Oncology (ESMO) Gynaecological; Jun 20-22, 2024; Florence, Italy; due to publications committee Mar 20, 2024; submission deadline Apr 3, 2024, 21:00 CET



International Society for Quality-of-Life Research (ISOQOL); Oct 13-16; Cologne, Germany; due to publications committee Mar 25, 2024; submission deadline Apr 8, 2024, CET